Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

@article{Cannon2006CardiovascularOW,
  title={Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison},
  author={Christopher P. Cannon and Sean P. Curtis and Garret A. FitzGerald and Henry Krum and Amarjot Kaur and James A. Bolognese and Alise S. Reicin and Claire Bombardier and Michael E. Weinblatt and D{\'e}sir{\'e}e van der Heijde and Erland Erdmann and Loren Laine},
  journal={The Lancet},
  year={2006},
  volume={368},
  pages={1771-1781}
}
Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
TLDR
Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg, and resulted in similar efficacy.
Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis
TLDR
The benefit-risk profile of diclofenac was comparable to other treatments used for pain relief in OA and RA; benefits and risks vary in individuals and need consideration when making treatment decisions.
Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
TLDR
The drug was associated with fewer uncomplicated upper gastrointestinal adverse events than nonselective NSAIDs, and was noninferior to diclofenac in terms of the rate of thrombotic cardiovascular events.
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).
TLDR
Long-term etoricoxib use is associated with a risk of thrombotic CV events comparable with that of diclofenac, but a greater risk of renovascular AEs but a more favourable GI/liver tolerability profile.
A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo
TLDR
Etoricoxib was comparable to placebo, celecoxib, and ibuprofen for effects on the CV risk markers measured, and was not different from Placebo, cele Coxib, or ibup rofen for any biomarker.
Efficacy and safety of etoricoxib in the treatment of osteoarthritis
  • A. Sebba
  • Medicine
    Expert review of clinical pharmacology
  • 2008
TLDR
Large-scale studies addressing the efficacy, GI tolerability and potential for CV events with etoricoxib have now been published, and several patient types appear to benefit, including those with CV risk factors and those requiring gastroprotective agents.
Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs
TLDR
It appears that the risk for cardiovascular events in arthritis patients on licensed doses of NSAIDs varies considerably and is likely to depend on the individual compound.
Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial
TLDR
A two-part extension of the initial 12-week treatment study found that etoricoxib was more effective than naproxen or placebo in treating rheumatoid arthritis was performed to monitor tolerability and examine long-term efficacy.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 69 REFERENCES
Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
TLDR
Single daily doses of valdecoxib 20 and 40 mg provided efficacy comparable to that of diclofenac, with a superior upper GI safety profile in the long-term treatment of RA patients.
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
TLDR
In the treatment of osteoarthritis, celecoxib is as effective as the nonspecific NSAIDs naproxen and diclofenac, but has significantly fewer serious upper gastrointestinal events.
Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis
TLDR
The data indicate that administration of valdecoxib offers similar efficacy for the treatment of osteoarthritis but improved upper-gastrointestinal safety compared with the conventional NSAIDs, ibuprofen and diclofenac, based on the significantly lower incidence of gastroduodenal ulcers detected by endoscopy.
A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
TLDR
In this study, etoricoxib 90 mg once daily was more effective than either placebo or naproxen 500 mg twice daily for treating patients with RA over 12 weeks and was generally well tolerated in patients withRA.
Efficacy and Tolerability Profile of Etoricoxib in Patients with Osteoarthritis: A Randomized, Double-blind, Placebo and Active-comparator Controlled 12-Week Efficacy Trial
TLDR
Etoricoxib showed rapid and durable treatment effects in patients with OA of the knee or hip and was generally well tolerated.
COMPARISON OF UPPER GASTROINTESTINAL TOXICITY OF ROFECOXIB AND NAPROXEN IN PATIENTS WITH RHEUMATOID ARTHRITIS
A BSTRACT Background Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who are taking nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We assessed
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
TLDR
Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups.
...
1
2
3
4
5
...